Shares of Gamida Cell Ltd. (NASDAQ:GMDA – Get Rating) have been assigned a consensus rating of “Buy” from the seven ratings firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $15.00.
Several research analysts recently commented on the stock. JMP Securities reiterated a “buy” rating and set a $17.00 price objective on shares of Gamida Cell in a research note on Tuesday, February 1st. HC Wainwright reiterated a “buy” rating and set a $22.00 price objective on shares of Gamida Cell in a research note on Wednesday, March 16th. Finally, Zacks Investment Research lowered shares of Gamida Cell from a “buy” rating to a “hold” rating in a research note on Monday, April 4th.
Shares of GMDA traded up $0.05 during mid-day trading on Tuesday, hitting $2.37. The company’s stock had a trading volume of 2,797 shares, compared to its average volume of 959,033. The company’s 50-day moving average is $3.51 and its 200-day moving average is $3.21. Gamida Cell has a 52-week low of $2.10 and a 52-week high of $7.09. The firm has a market capitalization of $140.30 million, a price-to-earnings ratio of -1.64 and a beta of 1.82. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 1.63.
Institutional investors have recently modified their holdings of the business. Parametric Portfolio Associates LLC increased its stake in shares of Gamida Cell by 10.7% in the fourth quarter. Parametric Portfolio Associates LLC now owns 32,230 shares of the company’s stock worth $82,000 after acquiring an additional 3,105 shares during the period. Bank of New York Mellon Corp acquired a new stake in shares of Gamida Cell in the third quarter worth $39,000. Cubist Systematic Strategies LLC increased its stake in shares of Gamida Cell by 54.5% in the third quarter. Cubist Systematic Strategies LLC now owns 33,523 shares of the company’s stock worth $131,000 after acquiring an additional 11,821 shares during the period. Stifel Financial Corp acquired a new stake in shares of Gamida Cell in the fourth quarter worth $37,000. Finally, Royal Bank of Canada increased its stake in shares of Gamida Cell by 21.0% in the third quarter. Royal Bank of Canada now owns 90,726 shares of the company’s stock worth $356,000 after acquiring an additional 15,745 shares during the period. Institutional investors and hedge funds own 47.12% of the company’s stock.
Gamida Cell Company Profile (Get Rating)
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia.
- Get a free copy of the StockNews.com research report on Gamida Cell (GMDA)
- High-Yield Deep-Value LCI Industries Exceeds All Expectations
- Shopify (NYSE: SHOP) Approaches Key Support Level
- Intuitive Surgical is an Intuitive Buy
- Follow The Money To Cigna
- The Low In Lordstown Motors May Not Be The Last
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.